Skip to main content

Table 1 Characteristics of the study patients and controls

From: Isolation and Quantification of Blood Apoptotic Bodies, a Non-invasive Tool to Evaluate Apoptosis in Patients with Ischemic Stroke and Neurodegenerative Diseases

Subject code Neurological disease Gender Age Clinical features at time of blood collection
IS1 Ischemic stroke Male 82 Acute phase (undetermined etiology), occlusion of left cerebral artery, affected cerebral volume: 57,835 cm3
IS2 Ischemic stroke Female 55 Acute phase (undetermined etiology), occlusion of right cerebral artery, affected cerebral volume: 45,080 cm3
IS3 Ischemic stroke Male 57 Acute phase (cardioembolic etiology), occlusion of right cerebral artery, affected cerebral volume: 36,980 cm3
IS4 Ischemic stroke Male 64 Acute phase (cardioembolic etiology), occlusion of right cerebral artery, affected cerebral volume: 65,605 cm3
MS1 Multiple sclerosis Female 37 Relapse episode (early RRMSa type)
MS2 Multiple sclerosis Female 27 Relapse episode (early RRMS type)
MS3 Multiple sclerosis Male 34 Relapse episode (early RRMS type)
MS4 Multiple sclerosis Female 24 Relapse episode (early RRMS type)
PD1 Parkinson’s disease Female 65 H&Yb stage II (tremor-dominant type)
PD2 Parkinson’s disease Female 62 H&Y stage II (tremor-dominant type)
PD3 Parkinson’s disease Female 71 H&Y stage II (akinetic-rigid type)
PD4 Parkinson’s disease Male 75 H&Y stage II (akinetic-rigid type)
H1 Control Male 66 Healthy volunteer
H2 Control Female 75 Healthy volunteer
H3 Control Male 82 Healthy volunteer
H4 Control Female 62 Healthy volunteer
H5 Control Female 27 Healthy volunteer
H6 Control Male 36 Healthy volunteer
  1. Subject code, neurological disease, gender, age, clinical features at time of blood collection are shown. aRRMS relapsing-remitting multiple sclerosis. bH&Y Hoehn and Yahr scale
  2. Blood samples of isquemic patients were obtained within 5 h after symptom onset
  3. Blood extractions of patients with multiple sclerosis was carried out during the first manifestation, while those of patients with Parkinson’s diseases were performed after 7–12 years after diagnosis